Arrowgrass Capital Partners (US)’s Regeneron Pharmaceuticals REGN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,300	Closed	-$489K	–	410
2017 Q4	$489K	Buy	1,300 +1,287	+9,900%	+$521K	﹤0.01%	461
2017 Q3	$581K	Hold	13	–	–	﹤0.01%	516
2017 Q2	$638K	Sell	13 -8	-38%	-$3.5K	﹤0.01%	545
2017 Q1	$814K	Hold	21	–	–	0.01%	502
2016 Q4	$771K	Buy	+21	New	+$7.99K	0.01%	445
2015 Q4	–	Sell	-10	Closed	-$465K	–	453
2015 Q3	$465K	Hold	10	–	–	0.01%	397
2015 Q2	$510K	Buy	+10	New	+$4.88K	0.01%	454
2015 Q1	–	Sell	-4,300	Closed	-$1.76M	–	500
2014 Q4	$1.76M	Sell	4,300 -8,700	-67%	-$3.42M	0.03%	256
2014 Q3	$4.69M	Buy	+13,000	New	+$4.36M	0.11%	117

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s REGN Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 11,684 shares — an estimated $4.39M sold.

Arrowgrass Capital Partners (US) first reported a position in REGN in Q3 2015 and held it in 9 quarters. The position peaked at $5.37M in Q1 2017. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Arrowgrass Capital Partners (US) reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 11,684 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $4.39M.
Arrowgrass Capital Partners (US) first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Arrowgrass Capital Partners (US)'s Regeneron Pharmaceuticals position peaked at $5.37M in Q1 2017.
620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.